Verve Therapeutics, Inc. (NASDAQ: VERV) reported Q4 EPS of ($0.58), $0.10 better than the analyst estimate of ($0.68). Revenue for the quarter came in at $13.08 million versus the consensus estimate of $3.57 million.

For earnings history and earnings-related data on Verve Therapeutics, Inc. (VERV) click here.